{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:07:31Z","timestamp":1784920051915,"version":"3.55.0"},"reference-count":105,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Since 2000, several randomized controlled trials (RCTs) addressing treatment of infections due to Gram-negative bacilli (GNB) have been published. We reviewed RCTs targeting GNB infections published between 2000 and 2025, focusing on methodology, generalizability of results and impact on patient care. Included were phase 2\u20134 RCTs enrolling adults with complicated intrabdominal infections (cIAI), hospital-acquired pneumonia\/ventilator-associated pneumonia (HAP\/VAP), complicated urinary tract infections (cUTI) and\/or bloodstream infections (BSI). Sixty-eight studies were included. cIAIs and cUTIs were the most frequent infection syndromes studied [in 30 (44.1%) and 28 (41.2%) RCTs, respectively]. Forty-two (61.8%) studies used a double-blind design, and 30 (44.1%) entailed placebo administration. Non-inferiority was the most common pre-specified hypothesis tested (48 RCTs, 70.6%). Superiority was assessed in only four studies. Twenty-nine unique antibiotics were evaluated overall, with novel agents assessed in 43 studies (63.2%). Twelve RCTs targeted one or more specific pathogen, three of which (25.0%) addressed a single pathogen, Acinetobacter baumannii in two RCTs and Escherichia coli in one. All of the 12 studies focused on specific antimicrobial resistant pathogens: 3 (25.0%) on third-generation cephalosporin-resistant GNB and\/or ESBL-producers and 9 (75.0%) on carbapenem-resistant pathogens.<\/jats:p>\n                  <jats:p>In summary, many high-quality RCTs of GNB infection treatment have been published in the 21st century. Results of many of these studies were influenced by methodological limitations and low rates of inclusion of multi-drug-resistant GNB, reducing generalizability to real-world clinical practice. Increased funding opportunities and regulatory modifications would facilitate conduct of real-world RCTs of GNB.<\/jats:p>","DOI":"10.1093\/jacamr\/dlag122","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:53:41Z","timestamp":1781178821000},"source":"Crossref","is-referenced-by-count":0,"title":["Gram-negative bacterial infection randomized controlled trials (RCTs) in the 21st century: characteristics and evolution"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8556-9180","authenticated-orcid":false,"given":"Fabian","family":"Patauner","sequence":"first","affiliation":[{"name":"Department of Medicine, Rutgers Robert Wood Johnson Medical School , New Brunswick, NJ 08901 ,","place":["USA"]},{"name":"Department of Precision Medicine, University of Campania \u2018L. Vanvitelli\u2019 , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeri","family":"Seok","sequence":"additional","affiliation":[{"name":"Department of Medicine, Rutgers Robert Wood Johnson Medical School , New Brunswick, NJ 08901 ,","place":["USA"]},{"name":"Korea University Medicine Department of Medicine, , Seoul ,","place":["South Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5071-9193","authenticated-orcid":false,"given":"Navaneeth","family":"Narayanan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Rutgers Robert Wood Johnson Medical School , New Brunswick, NJ 08901 ,","place":["USA"]},{"name":"Department of Pharmacy Practice and Administration, Rutgers Ernest Mario School of Pharmacy , Piscataway, NJ ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4780-6215","authenticated-orcid":false,"given":"Jason M","family":"Pogue","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of Michigan College of Pharmacy , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5381-3537","authenticated-orcid":false,"given":"Emanuele","family":"Durante-Mangoni","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine, University of Campania \u2018L. Vanvitelli\u2019 , Naples ,","place":["Italy"]},{"name":"AORN Ospedali dei Colli, Monaldi Hospital , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith S","family":"Kaye","sequence":"additional","affiliation":[{"name":"Department of Medicine, Rutgers Robert Wood Johnson Medical School , New Brunswick, NJ 08901 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"2026072414520837700_dlag122-B1","volume-title":"WHO Regional Office for Europe and European Centre for Disease Prevention and Control. Surveillance of Antimicrobial Resistance in Europe, 2024 Data: Executive Summary","author":"WHO","year":"2025"},{"key":"2026072414520837700_dlag122-B2","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.ajic.2025.03.005","article-title":"Community and hospital-acquired gram-negative bloodstream infections in non-ICU patients","volume":"53","author":"Keskilidou","year":"2025","journal-title":"Am J Infect Control"},{"key":"2026072414520837700_dlag122-B3","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2026072414520837700_dlag122-B4","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/jac\/dkq412","article-title":"Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins","volume":"66","author":"de Kraker","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2026072414520837700_dlag122-B5","doi-asserted-by":"publisher","first-page":"30319","DOI":"10.2807\/1560-7917.ES.2016.21.33.30319","article-title":"The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: a multicentre retrospective cohort study","volume":"21","author":"Stewardson","year":"2016","journal-title":"Euro Surveill"},{"key":"2026072414520837700_dlag122-B6","volume-title":"WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance","author":"WHO","year":"2024"},{"key":"2026072414520837700_dlag122-B7","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.3390\/molecules28041762","article-title":"A comprehensive overview of the antibiotics approved in the last two decades: retrospects and prospects","volume":"28","author":"Shi","year":"2023","journal-title":"Molecules"},{"key":"2026072414520837700_dlag122-B8","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant enterobacteriaceae infections: the TANGO II randomized clinical trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"key":"2026072414520837700_dlag122-B9","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2026072414520837700_dlag122-B10","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1185\/03007995.2012.748653","article-title":"Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study","volume":"28","author":"Vazquez","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"2026072414520837700_dlag122-B11","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1056\/NEJMc1807634","article-title":"Plazomicin for infections caused by carbapenem-resistant enterobacteriaceae","volume":"380","author":"McKinnell","year":"2019","journal-title":"N Engl J Med"},{"key":"2026072414520837700_dlag122-B12","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlaf131","article-title":"Aztreonam-avibactam for the treatment of serious infections caused by metallo-\u03b2-lactamase-producing gram-negative pathogens: a phase 3 randomized trial (ASSEMBLE)","volume":"7","author":"Daikos","year":"2025","journal-title":"JAC Antimicrob Resist"},{"key":"2026072414520837700_dlag122-B13","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026072414520837700_dlag122-B14","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S1473-3099(24)00499-7","article-title":"Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial","volume":"25","author":"Carmeli","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2026072414520837700_dlag122-B15","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/S1473-3099(23)00184-6","article-title":"Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)","volume":"23","author":"Kaye","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2026072414520837700_dlag122-B16","doi-asserted-by":"publisher","DOI":"10.1056\/evidoa2200131","article-title":"Colistin monotherapy versus combination therapy for carbapenem-resistant organisms","volume":"2","author":"Kaye","year":"2023","journal-title":"NEJM Evid"},{"key":"2026072414520837700_dlag122-B17","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant gram-negative bacteria: an open-label, randomised controlled trial","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2026072414520837700_dlag122-B18","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","article-title":"Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2026072414520837700_dlag122-B19","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/cid\/cit253","article-title":"Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial","volume":"57","author":"Durante-Mangoni","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2026072414520837700_dlag122-B20","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"2026072414520837700_dlag122-B21","doi-asserted-by":"publisher","first-page":"107357","DOI":"10.1016\/j.ijid.2024.107357","article-title":"A phase III, randomized, controlled noninferiority trial to study the efficacy and safety of imipenem\/cilastatin\/relebactam (IMI\/REL) vs piperacillin\/tazobactam (PIP\/TAZ) in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP)","volume":"153","author":"Li","year":"2025","journal-title":"Int J Infect Dis"},{"key":"2026072414520837700_dlag122-B22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2026072414520837700_dlag122-B23","doi-asserted-by":"publisher","first-page":"e4539","DOI":"10.1093\/cid\/ciaa803","article-title":"A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem\/cilastatin\/relebactam versus piperacillin\/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 study)","volume":"73","author":"Titov","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026072414520837700_dlag122-B24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1186\/s13054-019-2627-y","article-title":"Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (magic bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial","volume":"23","author":"Cisneros","year":"2019","journal-title":"Crit Care"},{"key":"2026072414520837700_dlag122-B25","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2026072414520837700_dlag122-B26","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2026072414520837700_dlag122-B27","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.diagmicrobio.2010.05.012","article-title":"Comparison of tigecycline with imipenem\/cilastatin for the treatment of hospital-acquired pneumonia","volume":"68","author":"Freire","year":"2010","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2026072414520837700_dlag122-B28","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1097\/CCM.0b013e3181691b99","article-title":"Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study","volume":"36","author":"Chastre","year":"2008","journal-title":"Crit Care Med"},{"key":"2026072414520837700_dlag122-B29","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1097\/01.CCM.0B013E31816203D6","article-title":"Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia","volume":"36","author":"Heyland","year":"2008","journal-title":"Crit Care Med"},{"key":"2026072414520837700_dlag122-B30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s15010-006-5020-0","article-title":"Piperacillin\/tazobactam vs imipenem\/cilastatin in the treatment of nosocomial pneumonia\u2013a double blind prospective multicentre study","volume":"34","author":"Schmitt","year":"2006","journal-title":"Infection"},{"key":"2026072414520837700_dlag122-B31","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1016\/j.rmed.2006.01.004","article-title":"Comparison of piperacillin\/tazobactam and imipenem\/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia","volume":"100","author":"Joshi","year":"2006","journal-title":"Respir Med"},{"key":"2026072414520837700_dlag122-B32","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1128\/AAC.47.11.3442-3447.2003","article-title":"Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study","volume":"47","author":"Zanetti","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2026072414520837700_dlag122-B33","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/s0149-2918(03)80091-7","article-title":"Levofloxacin compared with imipenem\/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study","volume":"25","author":"West","year":"2003","journal-title":"Clin Ther"},{"key":"2026072414520837700_dlag122-B34","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ijid.2022.08.003","article-title":"A phase III, multicenter, double-blind, randomized clinical trial to evaluate the efficacy and safety of ceftolozane\/tazobactam plus metronidazole versus meropenem in Chinese participants with complicated intra-abdominal infections","volume":"123","author":"Sun","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2026072414520837700_dlag122-B35","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/cid\/ciy1029","article-title":"IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections","volume":"69","author":"Solomkin","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026072414520837700_dlag122-B36","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ijantimicag.2017.01.010","article-title":"A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia","volume":"49","author":"Qin","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2026072414520837700_dlag122-B37","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating Gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg"},{"key":"2026072414520837700_dlag122-B38","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026072414520837700_dlag122-B39","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2026072414520837700_dlag122-B40","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1089\/sur.2012.017","article-title":"Prospective, randomized, study of ampicillin-sulbactam versus moxifloxacin monotherapy for the treatment of community-acquired complicated intra-abdominal infections","volume":"14","author":"Chen","year":"2013","journal-title":"Surg Infect (Larchmt)"},{"key":"2026072414520837700_dlag122-B41","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1093\/jac\/dks523","article-title":"Comparative study of the efficacy and safety of ceftazidime\/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial","volume":"68","author":"Lucasti","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2026072414520837700_dlag122-B42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ijantimicag.2012.08.013","article-title":"Randomised clinical trial of moxifloxacin versus ertapenem in complicated intra-abdominal infections: results of the PROMISE study","volume":"41","author":"De Waele","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"2026072414520837700_dlag122-B43","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/1471-2334-10-217","article-title":"Efficacy and safety of tigecycline monotherapy vs. Imipenem\/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial","volume":"10","author":"Chen","year":"2010","journal-title":"BMC Infect Dis"},{"key":"2026072414520837700_dlag122-B44","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1111\/j.1469-0691.2010.03122.x","article-title":"A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections","volume":"16","author":"Towfigh","year":"2010","journal-title":"Clin Microbiol Infect"},{"key":"2026072414520837700_dlag122-B45","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1089\/sur.2011.048","article-title":"Efficacy of tigecycline versus ceftriaxone plus metronidazole for the treatment of complicated intra-abdominal infections: results from a randomized, controlled trial","volume":"13","author":"Qvist","year":"2012","journal-title":"Surg Infect (Larchmt)"},{"key":"2026072414520837700_dlag122-B46","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.clinthera.2008.04.019","article-title":"Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study","volume":"30","author":"Lucasti","year":"2008","journal-title":"Clin Ther"},{"key":"2026072414520837700_dlag122-B47","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s15010-007-6237-2","article-title":"A randomized prospective study of cefepime plus metronidazole with imipenem-cilastatin in the treatment of intra-abdominal infections","volume":"35","author":"Garbino","year":"2007","journal-title":"Infection"},{"key":"2026072414520837700_dlag122-B48","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1089\/sur.2006.030","article-title":"Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin\/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults","volume":"8","author":"Namias","year":"2007","journal-title":"Surg Infect (Larchmt)"},{"key":"2026072414520837700_dlag122-B49","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/01.sla.0000230024.84190.a8","article-title":"Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections","volume":"244","author":"Malangoni","year":"2006","journal-title":"Ann Surg"},{"key":"2026072414520837700_dlag122-B50","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.gassur.2005.06.015","article-title":"Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention","volume":"10","author":"Dela Pena","year":"2006","journal-title":"J Gastrointest Surg"},{"key":"2026072414520837700_dlag122-B51","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/1471-2334-5-88","article-title":"A multicenter trial of the efficacy and safety of tigecycline versus imipenem\/cilastatin in patients with complicated intra-abdominal infections [study ID numbers: 3074A1-301-WW; ClinicalTrials.gov identifier: NCT00081744]","volume":"5","author":"Oliva","year":"2005","journal-title":"BMC Infect Dis"},{"key":"2026072414520837700_dlag122-B52","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S1015-9584(09)60039-7","article-title":"Randomized comparison of piperacillin\/tazobactam versus imipenem\/cilastatin in the treatment of patients with intra-abdominal infection","volume":"27","author":"Erasmo","year":"2004","journal-title":"Asian J Surg"},{"key":"2026072414520837700_dlag122-B53","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/01.SLA.0000048551.32606.73","article-title":"Ertapenem versus piperacillin\/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial","volume":"237","author":"Solomkin","year":"2003","journal-title":"Ann Surg"},{"key":"2026072414520837700_dlag122-B54","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/00000658-200101000-00013","article-title":"Results of a clinical trial of clinafloxacin versus imipenem\/cilastatin for intraabdominal infections","volume":"233","author":"Solomkin","year":"2001","journal-title":"Ann Surg"},{"key":"2026072414520837700_dlag122-B55","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s150100070027","article-title":"Cefminox versus metronidazole plus gentamicin intra-abdominal infections: a prospective randomized controlled clinical trial","volume":"28","author":"Torres","year":"2000","journal-title":"Infection"},{"key":"2026072414520837700_dlag122-B56","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1056\/NEJMoa2304748","article-title":"Cefepime-taniborbactam in complicated urinary tract infection","volume":"390","author":"Wagenlehner","year":"2024","journal-title":"N Engl J Med"},{"key":"2026072414520837700_dlag122-B57","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1093\/cid\/ciac704","article-title":"Sulopenem for the treatment of complicated urinary tract infections including pyelonephritis: a phase 3, randomized trial","volume":"76","author":"Dunne","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026072414520837700_dlag122-B58","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/jama.2022.17034","article-title":"Effect of cefepime\/enmetazobactam vs piperacillin\/tazobactam on clinical cure and microbiological eradication in patients with complicated urinary tract infection or acute pyelonephritis: a randomized clinical trial","volume":"328","author":"Kaye","year":"2022","journal-title":"JAMA"},{"key":"2026072414520837700_dlag122-B59","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa2105462","article-title":"Oral tebipenem pivoxil hydrobromide in complicated urinary tract infection","volume":"386","author":"Eckburg","year":"2022","journal-title":"N Engl J Med"},{"key":"2026072414520837700_dlag122-B60","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.37277","article-title":"Effectiveness of fosfomycin for the treatment of multidrug-resistant Escherichia coli bacteremic urinary tract infections: a randomized clinical trial","volume":"5","author":"Sojo-Dorado","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026072414520837700_dlag122-B61","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1093\/cid\/ciz181","article-title":"Fosfomycin for injection (ZTI-01) versus piperacillin-tazobactam for the treatment of complicated urinary tract infection including acute pyelonephritis: ZEUS, A phase 2\/3 randomized trial","volume":"69","author":"Kaye","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2026072414520837700_dlag122-B62","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1056\/NEJMoa1801467","article-title":"Once-daily plazomicin for complicated urinary tract infections","volume":"380","author":"Wagenlehner","year":"2019","journal-title":"N Engl J Med"},{"key":"2026072414520837700_dlag122-B63","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2026072414520837700_dlag122-B64","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1001\/jama.2018.0438","article-title":"Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA"},{"key":"2026072414520837700_dlag122-B65","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026072414520837700_dlag122-B66","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"2026072414520837700_dlag122-B67","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3346\/jkms.2012.27.5.476","article-title":"Comparison of ertapenem and ceftriaxone therapy for acute pyelonephritis and other complicated urinary tract infections in Korean adults: a randomized, double-blind, multicenter trial","volume":"27","author":"Park","year":"2012","journal-title":"J Korean Med Sci"},{"key":"2026072414520837700_dlag122-B68","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1179\/joc.2010.22.6.384","article-title":"Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis","volume":"22","author":"Redman","year":"2010","journal-title":"J Chemother"},{"key":"2026072414520837700_dlag122-B69","doi-asserted-by":"publisher","first-page":"3782","DOI":"10.1128\/AAC.00837-08","article-title":"Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis","volume":"53","author":"Naber","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2026072414520837700_dlag122-B70","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1185\/030079907X233340","article-title":"A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and\/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis","volume":"23","author":"Klausner","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"2026072414520837700_dlag122-B71","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1159\/000084432","article-title":"Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections","volume":"74","author":"Carmignani","year":"2005","journal-title":"Urol Int"},{"key":"2026072414520837700_dlag122-B72","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1128\/AAC.46.9.2895-2900.2002","article-title":"Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study","volume":"46","author":"Tomera","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2026072414520837700_dlag122-B73","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/s0090-4295(02)01664-3","article-title":"A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults","volume":"60","author":"Jimenez-Cruz","year":"2002","journal-title":"Urology"},{"key":"2026072414520837700_dlag122-B74","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/s0149-2918(02)85019-6","article-title":"A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis","volume":"24","author":"Cox","year":"2002","journal-title":"Clin Ther"},{"key":"2026072414520837700_dlag122-B75","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.cmi.2024.10.025","article-title":"A phase 3 randomized trial of sulopenem vs. ertapenem in patients with complicated intra-abdominal infections","volume":"31","author":"Dunne","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"2026072414520837700_dlag122-B76","author":"Global AMR R&D Hub & WHO"},{"key":"2026072414520837700_dlag122-B77","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/EDE.0000000000000564","article-title":"Biases in randomized trials: a conversation between trialists and epidemiologists","volume":"28","author":"Mansournia","year":"2017","journal-title":"Epidemiology"},{"key":"2026072414520837700_dlag122-B78","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40560-016-0151-6","article-title":"Designing phase 3 sepsis trials: application of learned experiences from critical care trials in acute heart failure","volume":"4","author":"Mebazaa","year":"2016","journal-title":"J Intensive Care"},{"key":"2026072414520837700_dlag122-B79"},{"key":"2026072414520837700_dlag122-B80","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf459","article-title":"Clinical practice guideline by Infectious Diseases Society of America (IDSA): 2025 guideline on management and treatment of complicated urinary tract infections: introduction and methods","author":"Trautner","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026072414520837700_dlag122-B81","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1007\/s00134-017-4802-4","article-title":"Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: a perspective from COMBACTE\u2019s STAT-net","volume":"43","author":"Timsit","year":"2017","journal-title":"Intensive Care Med"},{"key":"2026072414520837700_dlag122-B82","volume-title":"CDC. COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022","author":"U.S. Department of Health and Human Services, CDC","year":"2022"},{"key":"2026072414520837700_dlag122-B83","volume-title":"Global Antibiotic Resistance Surveillance Report 2025: WHO Global Antimicrobial Resistance and use Surveillance System (GLASS)","author":"WHO","year":"2025"},{"key":"2026072414520837700_dlag122-B84","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2020.1166","article-title":"Estimated research and development investment needed to bring a new medicine to market, 2009\u20132018","volume":"323","author":"Wouters","year":"2020","journal-title":"JAMA"},{"key":"2026072414520837700_dlag122-B85","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/s43856-025-01056-6","article-title":"War impact on antimicrobial resistance and bacteriological profile of wound infections in Ukraine","volume":"5","author":"Holubnycha","year":"2025","journal-title":"Commun Med"},{"key":"2026072414520837700_dlag122-B86","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S1473-3099(23)00264-5","article-title":"Ukraine war and antimicrobial resistance","volume":"23","author":"Petrosillo","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2026072414520837700_dlag122-B87","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/S2213-2600(23)00052-8","article-title":"Platform trials: the future of medical research?","volume":"11","author":"Burki","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026072414520837700_dlag122-B88","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med"},{"key":"2026072414520837700_dlag122-B89","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1056\/NEJMra1510061","article-title":"Adaptive designs for clinical trials","volume":"375","author":"Bhatt","year":"2016","journal-title":"N Engl J Med"},{"key":"2026072414520837700_dlag122-B90","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3390\/curroncol32060318","article-title":"The design of a patient-centered hierarchal composite outcome for a multi-center randomized controlled trial in metastatic bone disease","volume":"32","author":"Farrukh","year":"2025","journal-title":"Curr Oncol"},{"key":"2026072414520837700_dlag122-B91","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJMoa2304968","article-title":"Ferric carboxymaltose in heart failure with iron deficiency","volume":"389","author":"Mentz","year":"2023","journal-title":"N Engl J Med"},{"key":"2026072414520837700_dlag122-B92","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300286","article-title":"Dapagliflozin in myocardial infarction without diabetes or heart failure","volume":"3","author":"James","year":"2024","journal-title":"NEJM Evid"},{"key":"2026072414520837700_dlag122-B93","doi-asserted-by":"publisher","first-page":"4378","DOI":"10.1093\/eurheartj\/ehac472","article-title":"Influenza vaccination strategy in acute coronary syndromes: the VIP-ACS trial","volume":"43","author":"Fonseca","year":"2022","journal-title":"Eur Heart J"},{"key":"2026072414520837700_dlag122-B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2022.106598","article-title":"Short- versus standard-course intravenous antibiotics for peri-prosthetic joint infections managed with debridement and implant retention: a randomised pilot trial using a desirability of outcome ranking (DOOR) endpoint","volume":"60","author":"Manning","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2026072414520837700_dlag122-B95","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1001\/jamapediatrics.2021.5547","article-title":"Short- vs standard-course outpatient antibiotic therapy for community-acquired pneumonia in children: the SCOUT-CAP randomized clinical trial","volume":"176","author":"Williams","year":"2022","journal-title":"JAMA Pediatr"},{"key":"2026072414520837700_dlag122-B96","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.cmi.2025.11.027","article-title":"Comparing different methods for analysing hierarchical composite endpoints: two illustrative case studies with post hoc analyses of the BALANCE (bacteraemia antibiotic length actually needed for clinical effectiveness) and CAMERA2 (combination antibiotics for methicillin-resistant staphylococcus aureus) randomized clinical trials","volume":"32","author":"Ong","year":"2026","journal-title":"Clin Microbiol Infect"},{"key":"2026072414520837700_dlag122-B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103474","article-title":"Hierarchical composite endpoints in clinical trials for multimorbid older adults","volume":"88","author":"Vart","year":"2025","journal-title":"eClinicalMedicine"},{"key":"2026072414520837700_dlag122-B98","doi-asserted-by":"publisher","first-page":"e319","DOI":"10.1093\/cid\/ciaf314","article-title":"Making sense of hierarchical composite end points in randomized clinical trials\u2014a primer for infectious diseases clinicians and researchers","volume":"81","author":"Ong","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026072414520837700_dlag122-B99","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.cmi.2023.05.003","article-title":"Unlocking the DOOR\u2014how to design, apply, analyse, and interpret desirability of outcome ranking endpoints in infectious diseases clinical trials","volume":"29","author":"Ong","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"2026072414520837700_dlag122-B100","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1086\/647952","article-title":"Antimicrobial susceptibility testing: a review of general principles and contemporary practices","volume":"49","author":"Jorgensen","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2026072414520837700_dlag122-B101","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0140-6736(24)02081-6","article-title":"Multidrug-resistant Gram-negative bacterial infections","volume":"405","author":"Macesic","year":"2025","journal-title":"Lancet"},{"key":"2026072414520837700_dlag122-B102","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1093\/cid\/ciae234","article-title":"Rapid diagnostic tests and antimicrobial stewardship programs for the management of bloodstream infection: what is their relative contribution to improving clinical outcomes? A systematic review and network meta-analysis","volume":"79","author":"Peri","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026072414520837700_dlag122-B103","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/cid\/ciw649","article-title":"The effect of molecular rapid diagnostic testing on clinical outcomes in bloodstream infections: a systematic review and meta-analysis","volume":"64","author":"Timbrook","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026072414520837700_dlag122-B104","author":"Rossolini"},{"key":"2026072414520837700_dlag122-B105","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1001\/jama.2023.4221","article-title":"Emulation of randomized clinical trials with nonrandomized database analyses: results of 32 clinical trials","volume":"329","author":"Wang","year":"2023","journal-title":"JAMA"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/4\/dlag122\/69888320\/dlag122.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/4\/dlag122\/69888320\/dlag122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T18:52:15Z","timestamp":1784919135000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlag122\/8740791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":105,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlag122","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,2]]},"article-number":"dlag122"}}